| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, University of Michigan, Ann Arbor, Michigan
Correspondence: For correspondence or reprints contact: Richard L. Wahl, MD, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, B 10412, Ann Arbor, MI 48109-0028.
ABSTRACT
The relationship between 3H-2-fluoro-2-deoxy-D-glucose (FDG) uptake and the proliferative rate of a human ovarian adenocarcinoma cell line (HTB77IP3) was examined in vitro. HTB77IP3 cells were plated and allowed to grow through lag, exponential and plateau phases. Proliferative rate assessed by DNA flow cytometry and 3H-thymidine in corporation was highest in the lag phase and fell significantly as the cells progressed from the exponential through plateau phases. By DNA flow cytometry, the proliferation index (% of S+G2/M phase cells) fell from 65% to 23%. Thymidine uptake per cell also declined, by 82%, from lag to plateau phase. By contrast, 3H-FDG uptake per cell was largely unchanged as the cells progressed through the cell growth cycle. Total 3H-FDG uptake was strongly correlated with the number of viable cancer cells present (r = 0.957). Total thymidine uptake, however, substantially underestimated the number of viable cancer cells present These in vitro differences in tracer up take suggest that in this adenocarcinoma cell line, FDG measures a substantially different parameter (viable cell number) than thymidine (proliferative rate) and that these differences may result in disparate findings on PET imaging of cancers using these two tracers. Our data for this in vitro system indicate that FDG uptake does not relate to the proliferative activity of cancer cells. However, FDG uptake is strongly related to the number of viable tumor cells.
FOOTNOTES
* Current address: Kotaro Higashi, MD, Department of Radiology, Kanazawa Medical University, Ishikawa 920-02, Japan.
This article has been cited by other articles:
|
|
 |
|
  D. Uesaka, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, Y. Fujibayashi, and H. Okazawa Evaluation of Dual-Time-Point 18F-FDG PET for Staging in Patients with Lung Cancer J. Nucl. Med., October 1, 2008; 49(10): 1606 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dimitrakopoulou-Strauss, P. Hohenberger, U. Haberkorn, H. R. Macke, M. Eisenhut, and L. G. Strauss 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG J. Nucl. Med., August 1, 2007; 48(8): 1245 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 44 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A.D. Smith, R. I. Sharma, A. M. Thompson, and F. E.M. Paulin Tumor 18F-FDG Incorporation Is Enhanced by Attenuation of P53 Function in Breast Cancer Cells In Vitro J. Nucl. Med., September 1, 2006; 47(9): 1525 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. van Waarde, L. B. Been, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Early Response of {sigma}-Receptor Ligands and Metabolic PET Tracers to 3 Forms of Chemotherapy: An In Vitro Study in Glioma Cells J. Nucl. Med., September 1, 2006; 47(9): 1538 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Shankar, J. M. Hoffman, S. Bacharach, M. M. Graham, J. Karp, A. A. Lammertsma, S. Larson, D. A. Mankoff, B. A. Siegel, A. Van den Abbeele, et al. Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials J. Nucl. Med., June 1, 2006; 47(6): 1059 - 1066. [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Abouzied, E. S. Crawford, and H. A. Nabi 18F-FDG Imaging: Pitfalls and Artifacts J. Nucl. Med. Technol., September 1, 2005; 33(3): 145 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wells, R. N. Gunn, C. Steel, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price 2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans Clin. Cancer Res., June 15, 2005; 11(12): 4341 - 4347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Leyton, J. R. Latigo, M. Perumal, H. Dhaliwal, Q. He, and E. O. Aboagye Early Detection of Tumor Response to Chemotherapy by 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography: The Effect of Cisplatin on a Fibrosarcoma Tumor Model In vivo Cancer Res., May 15, 2005; 65(10): 4202 - 4210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugiyama, H. Sakahara, K. Sato, N. Harada, D. Fukumoto, T. Kakiuchi, T. Hirano, E. Kohno, and H. Tsukada Evaluation of 3'-Deoxy-3'-18F-Fluorothymidine for Monitoring Tumor Response to Radiotherapy and Photodynamic Therapy in Mice J. Nucl. Med., October 1, 2004; 45(10): 1754 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, G. Glatting, and S. N. Reske Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker? J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck and S. N. Reske Cellular Origin and Molecular Mechanisms of 18F-FDG Uptake: Is There a Contribution of the Endothelium? J. Nucl. Med., March 1, 2004; 45(3): 461 - 463. [Full Text]
|
|
|
|
 |
|
 G. Antoch, G. M. Kaiser, A. B. Mueller, K. A. Metz, H. Zhang, H. Kuehl, S. Westermann, C. E. Broelsch, S. P. Mueller, A. Bockisch, et al. Intraoperative Radiation Therapy in Liver Tissue in a Pig Model: Monitoring with Dual-Modality PET/CT Radiology, March 1, 2004; 230(3): 753 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D L Francis, A Freeman, D Visvikis, D C Costa, S K Luthra, M Novelli, I Taylor, and P J Ell In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography Gut, November 1, 2003; 52(11): 1602 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer J. Nucl. Med., May 1, 2003; 44(5): 690 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Demura, T. Tsuchida, T. Ishizaki, S. Mizuno, Y. Totani, S. Ameshima, I. Miyamori, M. Sasaki, and Y. Yonekura 18F-FDG Accumulation with PET for Differentiation Between Benign and Malignant Lesions in the Thorax J. Nucl. Med., April 1, 2003; 44(4): 540 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kitagawa, S. Nishizawa, K. Sano, T. Ogasawara, M. Nakamura, N. Sadato, M. Yoshida, and Y. Yonekura Prospective Comparison of 18F-FDG PET with Conventional Imaging Modalities (MRI, CT, and 67Ga Scintigraphy) in Assessment of Combined Intraarterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 198 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Buck, H. H. Schirrmeister, C.-A. Guhlmann, C. G. Diederichs, C. Shen, I. Buchmann, J. Kotzerke, D. Birk, T. Mattfeldt, and S. N. Reske Ki-67 Immunostaining in Pancreatic Cancer and Chronic Active Pancreatitis: Does In Vivo FDG Uptake Correlate with Proliferative Activity? J. Nucl. Med., May 1, 2001; 42(5): 721 - 725. [Abstract] [Full Text]
|
|
|
|
|
|
N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Janicke, W. Nathrath, and M. Schwaiger Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis J. Nucl. Med., January 1, 2001; 42(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Higashi, S. J. Fisher, R. S. Brown, K. Nakada, G. L. Walter, and R. L. Wahl Evaluation of the Early Effect of Local Irradiation on Normal Rodent Bone Marrow Metabolism Using FDG: Preclinical PET Studies J. Nucl. Med., December 1, 2000; 41(12): 2026 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Thie, K. F. Hubner, and G. T. Smith The Diagnostic Utility of the Lognormal Behavior of PET Standardized Uptake Values in Tumors J. Nucl. Med., October 1, 2000; 41(10): 1664 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al. Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Berger, S. A. Nicholson, F. Dehdashti, and B. A. Siegel FDG PET Evaluation of Mucinous Neoplasms: Correlation of FDG Uptake with Histopathologic Features Am. J. Roentgenol., April 1, 2000; 174(4): 1005 - 1008. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
